Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
Journal
Gut and liver
Journal Volume
17
Journal Issue
2
Pages
288 - 298
Date Issued
2023
Author(s)
Lin, Yen-Chun
Lee, Tai-Ju
Abstract
Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort.
Subjects
Autoimmune diseases; Hepatitis B; Rituximab
SDGs
Publisher
EDITORIAL OFFICE GUT & LIVER
Type
journal article